Risk of Third Malignancies and Death After a Second Malignancy in Retinoblastoma Survivors
Overview
Affiliations
Retinoblastoma patients have a strongly increased risk of second malignancies, and survivors with a third or subsequent malignancy are increasingly observed. However, it has not been examined whether survivors who developed a second malignancy have a greater risk of a subsequent malignancy. On the basis of the Dutch retinoblastoma registry, the risk of a third malignancy was compared with cancer risk in the Dutch population. Cox model analysis with a time-dependent covariate was used to compare the subsequent malignancy risk and survival among patients with and without a second malignancy. Risk of a third malignancy was increased 8-fold compared with the general population. The hazard ratio (HR) of a third malignancy after a second malignancy was more than 7-fold increased compared to the risk of a second malignancy after retinoblastoma. Radiotherapy increased the risk 3-fold. A third malignancy was associated with worse survival compared with survival of patients only diagnosed with a second malignancy (HR=5.0). Survivors of retinoblastoma who already developed a second primary malignancy have an even higher risk of subsequent primary malignancies than retinoblastoma survivors without a second malignancy. Treating physicians and patients should be aware of this higher risk.
Perez-Becerra J, Rodriguez-Machuca V, Gonzalez-Rodriguez M, Brukman-Jimenez S, Corona-Rivera A, Ramirez-Corona J Int J Mol Sci. 2024; 25(22).
PMID: 39596402 PMC: 11594721. DOI: 10.3390/ijms252212338.
Ribeiro K, Veiga L, Carvalho Filho N, Morton L, Kleinerman R, Antoneli C Int J Cancer. 2024; 156(1):69-78.
PMID: 39138799 PMC: 11537822. DOI: 10.1002/ijc.35127.
Subsequent Malignant Neoplasms in Retinoblastoma Survivors.
Fabius A, van Hoefen Wijsard M, van Leeuwen F, Moll A Cancers (Basel). 2021; 13(6).
PMID: 33801943 PMC: 8001190. DOI: 10.3390/cancers13061200.
Friedman D, Hsu M, Moskowitz C, Francis J, Lis E, Fleischut M Pediatr Blood Cancer. 2020; 67(7):e28389.
PMID: 32386119 PMC: 8177753. DOI: 10.1002/pbc.28389.
Banerjee S, Pottenger E, Petriccione M, Chou J, Ford J, Sklar C Palliat Support Care. 2019; 18(3):322-331.
PMID: 31699178 PMC: 7205583. DOI: 10.1017/S1478951519000920.